VTGN - VistaGen Therapeutics GAAP EPS of -$1.52 misses by $1.16 revenue of $1.06M beats by $0.86M
2024-06-11 16:23:35 ET
More on VistaGen Therapeutics
- Vistagen Therapeutics: A Pipeline With Potential In Anxiety And Depression
- Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish
- Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments
- VistaGen Therapeutics Q4 Earnings Preview
- Vistagen reports positive results for mental fatigue treatment